Research ArticleArticle
Cytochrome P450 Architecture and Cysteine Nucleophile Placement Impact Raloxifene-Mediated Mechanism-Based Inactivation
Brooke M. VandenBrink, John A. Davis, Josh T. Pearson, Robert S. Foti, Larry C. Wienkers and Dan A. Rock
Molecular Pharmacology November 2012, 82 (5) 835-842; DOI: https://doi.org/10.1124/mol.112.080739
Brooke M. VandenBrink
Biochemistry and Biophysics Group, Departments of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington
John A. Davis
Biochemistry and Biophysics Group, Departments of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington
Josh T. Pearson
Biochemistry and Biophysics Group, Departments of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington
Robert S. Foti
Biochemistry and Biophysics Group, Departments of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington
Larry C. Wienkers
Biochemistry and Biophysics Group, Departments of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington
Dan A. Rock
Biochemistry and Biophysics Group, Departments of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Raloxifene-Selective P450 Inactivation
Brooke M. VandenBrink, John A. Davis, Josh T. Pearson, Robert S. Foti, Larry C. Wienkers and Dan A. Rock
Molecular Pharmacology November 1, 2012, 82 (5) 835-842; DOI: https://doi.org/10.1124/mol.112.080739
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement